trending Market Intelligence /marketintelligence/en/news-insights/trending/9zygyr4hcpwrh6vv2rdn3q2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

CTD applies to conduct trials of neurodegenerative disorder drug in Italy

L.K. Bennett: Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


CTD applies to conduct trials of neurodegenerative disorder drug in Italy

CTD Holdings Inc. filed a clinical trial application with Italy's drug regulator Agenzia Italiana del Farmaco to conduct a Phase 1/2 clinical trial of Trappsol Cyclo in Italy.

Trappsol Cyclo is intended for the treatment of Niemann-Pick disease type C, a rare genetic, neurodegenerative disorder that causes progressive deterioration of the nervous system.

CTD's plans for the trials include administering the drug intravenously to patients in Italy as young as two years old and into adulthood. The study will evaluate the safety and tolerability of three doses of the drug, its effects on the body and how the body metabolizes the drug.

Results will be checked for cholesterol synthesis and cholesterol degradation as well as clinical assessments of swallowing, lung function, cognitive ability and fine motor skills.

The product candidate previously received an orphan drug designation in both the EU and the U.S.